NCT02560753View on ClinicalTrials.gov

Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

May 30, 2016

Study Completion Date

June 30, 2016

Conditions
Alzheimer's Disease
Interventions
DRUG

T3D-959

The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)

Trial Locations (3)

28204

New Hope Clinical Research, Charlotte

33137

Miami Jewish Health Systems, Miami

33445

Brain Matters Research, Delray Beach

All Listed Sponsors
lead

T3D Therapeutics, Inc.

INDUSTRY

NCT02560753 - Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter